Search Results 861-870 of 17991 for sickle cell
Regenerative biotherapeutics are aimed at restoring damaged tissues, cells and organs that are at the root of most diseases. Mayo's strategy emphasizes ...
Mayo Clinic Proceedings, Kidney International publish consensus statement on new approach to identifying kidney disorder · Zooming in on rare bone cells that ...
Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...
A Study of the Safety of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program for use in Stem Cell Transplants to ...
This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns ...
Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib, cediranib maleate, and ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
Thrombolysis within the previous 30 days or known existing coagulopathy such as thrombocytopenia or hemoglobin diseases such as sickle cell anemia or ...
Marla Broadfoot, Ph.D. September 17, 2024. More Mayo neuroscience: Brain cells 'crosstalk' and cancer ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.